Agios Pharmaceuticals Inc logo

AGIO - Agios Pharmaceuticals Inc Share Price

$52.77 -0.2  -0.3%

Last Trade - 09/04/21

Large Cap
Market Cap £2.68bn
Enterprise Value £2.26bn
Revenue £148.2m
Position in Universe 1673rd / 6827
Unlock AGIO Revenue
Relative Strength (%)
1m +7.49%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -10.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
59.1 69.9 43.0 94.4 117.9 203.2 88.0 134.1 +28.0%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, AgiosPharmaceuticals Inc revenues increased 72% to $203.2M. Netloss decreased 20% to $327.4M. Revenues reflect Productrevenue, net increase from $59.9M to $121.1M, Collaborationrevenue related party increase of 74% to $68.3M. Lower netloss reflects Research and development decrease of 11% to$330.3M (expense), Research and development expensedecrease of 5% to $37.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


AGIO Revenue Unlock AGIO Revenue

Net Income

AGIO Net Income Unlock AGIO Revenue

Normalised EPS

AGIO Normalised EPS Unlock AGIO Revenue

PE Ratio Range

AGIO PE Ratio Range Unlock AGIO Revenue

Dividend Yield Range

AGIO Dividend Yield Range Unlock AGIO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
AGIO EPS Forecasts Unlock AGIO Revenue
Profile Summary

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated August 7, 2007
Public Since July 24, 2013
No. of Shareholders: 11
No. of Employees: 562
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 69,601,332
Free Float (0.0%)
Eligible for
AGIO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for AGIO
Upcoming Events for AGIO
Wednesday 28th April, 2021 Estimate
Q1 2021 Agios Pharmaceuticals Inc Earnings Release
Friday 28th May, 2021 Estimate
Agios Pharmaceuticals Inc Annual Shareholders Meeting
Wednesday 28th July, 2021 Estimate
Q2 2021 Agios Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for Agios Pharmaceuticals Inc
What is the Agios Pharmaceuticals Inc share price?

As of 09/04/21, shares in Agios Pharmaceuticals Inc are trading at $52.77, giving the company a market capitalisation of £2.68bn. This share price information is delayed by 15 minutes.

How has the Agios Pharmaceuticals Inc share price performed this year?

Shares in Agios Pharmaceuticals Inc are currently trading at $52.77 and the price has moved by 32.32% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Agios Pharmaceuticals Inc price has moved by -10.81% over the past year.

What are the analyst and broker recommendations for Agios Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Agios Pharmaceuticals Inc, there are there are currently 3 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Agios Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Agios Pharmaceuticals Inc next release its financial results?

Agios Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Agios Pharmaceuticals Inc dividend yield?

Agios Pharmaceuticals Inc does not currently pay a dividend.

Does Agios Pharmaceuticals Inc pay a dividend?

Agios Pharmaceuticals Inc does not currently pay a dividend.

When does Agios Pharmaceuticals Inc next pay dividends?

Agios Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Agios Pharmaceuticals Inc shares?

To buy shares in Agios Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Agios Pharmaceuticals Inc?

Shares in Agios Pharmaceuticals Inc are currently trading at $52.77, giving the company a market capitalisation of £2.68bn.

Where are Agios Pharmaceuticals Inc shares listed? Where are Agios Pharmaceuticals Inc shares listed?

Here are the trading details for Agios Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AGIO
What kind of share is Agios Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Agios Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Agios Pharmaceuticals Inc share price forecast 2021?

Shares in Agios Pharmaceuticals Inc are currently priced at $52.77. At that level they are trading at 22.97% discount to the analyst consensus target price of 0.00.

Analysts covering Agios Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -6.07 for the next financial year.

How can I tell whether the Agios Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Agios Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 27.83%. At the current price of $52.77, shares in Agios Pharmaceuticals Inc are trading at 18.08% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Agios Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Agios Pharmaceuticals Inc.

Who are the key directors of Agios Pharmaceuticals Inc?

Agios Pharmaceuticals Inc's management team is headed by:

David Schenkein - CHM
Paul Clancy - IND
Christopher Bowden - OTH
Kaye Foster - IND
Maykin Ho - IND
Ian Clark - IND
David Scadden - DRC
Jacqualyn Fouse - CEO
Jonathan Biller - CFO
Bruce Car - CSO
Darrin Miles - OTH
Who are the major shareholders of Agios Pharmaceuticals Inc?

Here are the top five shareholders of Agios Pharmaceuticals Inc based on the size of their shareholding:

Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 11.28% (7.88m shares)
Vanguard Health Care Fund Mutual Fund
Percentage owned: 9.22% (6.44m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.06% (5.63m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 6.12% (4.27m shares)
Bellevue Asset Management AG Investment Advisor
Percentage owned: 6.02% (4.20m shares)
Similar to AGIO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.